ENVB - CIK 0000890821
The table below shows Enveric Biosciences, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$8.14M | -$7.73M | -$14.09M | -$17.15M | -$11.46M | -$3.89M |
| Capital expenditure | - | - | $5.18K | $584.16K | $189.72K | - |
| Investing cash flow | - | - | $11.67K | -$584.16K | $2.19M | -$44.14K |
| Dividends paid | - | - | - | - | - | - |
Enveric Biosciences, Inc. reported operating cash flow of -$8.14M for fiscal year 2025. That is down 5.4% from -$7.73M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$2.70M (FY 2016) to -$8.14M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $10.58M | $7.67M | -$1.34M | $18.18M | $24.90M | $5.53M |